Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2011 | Original Paper

Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2011

Abstract

Purpose

PTEN, a tumor-suppressor gene located on chromosome 10q23.3 is implicated in multiple tumors including cervical carcinoma.

Methods

We examined 135 cervical cancer specimens for PTEN gene expression and promoter methylation using methylation-specific PCR and immunohistochemistry and also studied the mutation in PTEN gene through PCR-single-stranded conformational polymorphism. PTEN expression and its methylation status were also correlated with clinicopathologic parameters.

Results

The results showed an abnormal band on exon 5 and exon 9 of the PTEN gene. In PTEN gene, 61% specimen showed methylation. PTEN methylation was found in 39% cases of stage I, 60% of stage II, and 75% of stages III–IV. The correlation between PTEN methylation and clinical stage was found to be statistically significant (P = 0.003). Nuclear PTEN expression was detected in 84 of 135 (62%) cases of cervical carcinoma, and the remaining 51 of 135 (38%) cases were observed as expressional loss. The loss of PTEN expression was significantly correlated clinical stage (P = 0.001). Loss of PTEN expression was observed in 34 (41%) cases among 83 methylation positive cases, whereas among 52 methylation-negative cases, only 13 (25%) cases were seen as immunostaining negative with the statistically significant value (P = 0.05).

Conclusion

Promoter methylation and loss of PTEN expression occur frequently in carcinoma of uterine cervix. Our results suggest that PTEN plays an important role in the carcinogenesis of cervical cancer.

Alam MS, Rizvi MM (2011) Cancer of the uterine cervix and PTEN tumor suppressor gene. Lambert Academic Publishing, Germany

American Cancer Society (2009) Cancer facts & figures. American Cancer Society, Atlanta

Aneta JJ, Bożena K, Cyprian G, Urszula N (2010) TP53 Mutations in Endometrial Cancers: Relation to PTEN Gene Defects. Int J Gynecol Cancer 20(2):196–202CrossRef

Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70:209–262CrossRef

Cheung TH, Lo WK, Yim SF, Chan LK, Jeung MS, Chan CS, Cheung A, Chung TK, Wong YF (2004) Epigenetic and genetic alteration of PTEN in cervical neoplasm. Gynecol Oncol 93:621–627PubMedCrossRef

Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. In: IARC Cancer base No. 5, version 2.0. IARC Press, Lyon

Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK (1995) Loss of the chromosomal region 10q23–25 in prostate cancer. Cancer Res 55:4800–4803PubMed

Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660–3663PubMed

Guo CY, Xu XF, Wu JY, Liu SF (2008) PCR-SSCP-DNA sequencing mrthod in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 14(24):3804–3811PubMedCrossRef

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93:9821–9826PubMedCrossRef

Huang J, Kontos CD (2002) PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 277:10760–10766PubMedCrossRef

Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J (2010) EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol 48(4):238–245PubMed

Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N (2002) Activation of Akt/protein kinase B overcomes a G (2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22:7831–7841PubMedCrossRef

Kang YH, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82:285–291PubMed

Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S et al (1997) PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17:143–144PubMedCrossRef

Lazo PA (1999) The molecular genetics of cervical carcinoma. Br J Cancer 80:2008–2018PubMedCrossRef

Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRef

McConnachie G, Pass I, Walker SM, Downes CP (2003) Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J 371(3):947–955PubMedCrossRef

Mitra AB, Murty VS, Li RG, Pratap M, Luthra UK, Chaganti SK (1994) Allelotype analysis of cervical carcinoma. Cancer Res 54:4481–4487PubMed

National Cancer Registry Programme (2007) Consolidated report of hospital based cancer registries 2001–2003. ICMR, New Delhi

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Preacher KJ (2001) Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Available from http://www.quantpsy.org

Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187–4190PubMed

Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678–684PubMedCrossRef

Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J (1997) Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57:3657–3659PubMed

Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, Das S (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22–26PubMedCrossRef

Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor Lab. Press, plainview

Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri F (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178–1184PubMed

Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29–39PubMedCrossRef

Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362PubMedCrossRef

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRef

Wang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246–5250CrossRef

Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95:15587–15591PubMedCrossRef

Yang HJ, Liu SW, Wang Y, Tsang CK, Ngan YS (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinic-pathological data. BMC Cancer 6:212PubMedCrossRef

Zhang L, Liu T, Liu H, Gao J, Gu C (2000) Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer. Zhonghua Bing Li Xue Za Zhi 29:85–88PubMed

Title: Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population
Publication date: 01-08-2011
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-0994-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2011

Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery

Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers

Assessing the value of CAN-gene mutations using MALDI-TOF MS

Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer

Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page